肝纤维化逆转的研究进展

李满彪; 李金玉; 冯对平

doi:10.3969/j.issn.1001-5256.2023.01.030

肝纤维化逆转的研究进展

DOI: 10.3969/j.issn.1001-5256.2023.01.030

1.
山西医科大学医学影像学院，太原 030001
2.
山西医科大学第一医院肿瘤与血管介入科，太原 030001

基金项目:

山西省重点研发计划社会发展项目 (201903D321188);

山西省科学技术厅面上项目 (20210302123258)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李满彪负责拟定写作思路，检索文献，撰写论文；冯对平、李金玉负责指导、修改论文并最终定稿。

详细信息

通信作者:
冯对平, fengdp@sxmu.edu.cn (ORCID: 0000-0003-4516-3797)

计量
- 文章访问数: 2467
- HTML全文浏览量: 1815
- PDF下载量: 353
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-15
- 录用日期: 2022-07-14
- 出版日期: 2023-01-20

Research advances in the reversal of liver fibrosis

Manbiao LI¹,
Jinyu LI²,
Duiping FENG^{2
, ,
,}

1.
School of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China
2.
Department of Oncology and Vascular Intervention, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Social Development Project of Shanxi Key Research and Development Plan (201903D321188);

Department of Science and Technology of Shanxi Province, General Project (20210302123258)

More Information

Corresponding author: FENG Duiping, fengdp@sxmu.edu.cn (ORCID: 0000-0003-4516-3797)

摘要

摘要: 任何病因引起的慢性肝损伤都会导致肝纤维化，过去认为肝纤维化是一种静态的、不可逆转的病理生理过程。近年来，随着分子生物学的飞速发展，以及对肝脏微观层面的不断深入研究，越来越多的证据表明肝纤维化是一种动态的、可逆的过程。本文回顾了不同方法评价各种病因导致的肝纤维化逆转的报道，总结了肝纤维化的发病机制及其逆转的机制，并回顾了逆转的治疗药物，归纳目前肝纤维化的评估方法，最后认为及时清除或控制潜在病因，肝纤维化会出现不同程度的逆转。
- 肝硬化 /
- 肝星状细胞 /
- 组织学 /
- 血清学
Abstract: Chronic liver injury caused by any etiology will lead to liver fibrosis, and it was believed in the past that liver fibrosis is a static and irreversible pathophysiological process. In recent years, with the rapid development of molecular biology and the in-depth research on the microscopic aspect of the liver, more and more evidence has shown that liver fibrosis is a dynamic and reversible process. This article reviews the reports of different methods for evaluating the reversal of liver fibrosis caused by various etiologies, summarizes the pathogenesis and reversal mechanism of liver fibrosis, reviews the therapeutic drugs for reversal, and summarizes the current evaluation methods for liver fibrosis, and finally, it is believed that timely clearance or control of potential etiology may help to achieve the reversal of liver fibrosis to a certain degree.
- Liver Cirrhosis /
- Hepatic Stellate Cells /
- Histology /
- Serology

HTML全文

参考文献(39)

[1]	AYDIN MM, AKÇALI KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1): 14-21. DOI: 10.5152/tjg.2018.17330.
[2]	ZOUBEK ME, TRAUTWEIN C, STRNAD P. Reversal of liver fibrosis: From fiction to reality[J]. Best Pract Res Clin Gastroenterol, 2017, 31(2): 129-141. DOI: 10.1016/j.bpg.2017.04.005.
[3]	CHEN S, ZHOU J, WU X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B[J]. Hepatol Int, 2021, 15(3): 611-620. DOI: 10.1007/s12072-021-10162-1.
[4]	ZAKAREYA T, ELHELBAWY M, ELZOHRY H, et al. Long-term impact of hepatitis C virus eradication on liver stiffness in egyptian patients[J]. Can J Gastroenterol Hepatol, 2021, 2021: 4961919. DOI: 10.1155/2021/4961919.
[5]	NONO JK, FU K, MPOTJE T, et al. Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models[J]. Sci Rep, 2020, 10(1): 10638. DOI: 10.1038/s41598-020-67514-4.
[6]	DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ, et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterology, 2003, 124(1): 105-117. DOI: 10.1053/gast.2003.50013.
[7]	ABAYLI B, ABAYLI C, GENCDAL G. Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B[J]. World J Gastrointest Pharmacol Ther, 2021, 12(2): 32-39. DOI: 10.4292/wjgpt.v12.i2.32.
[8]	SUN YM, CHEN SY, YOU H. Regression of liver fibrosis: evidence and challenges[J]. Chin Med J (Engl), 2020, 133(14): 1696-1702. DOI: 10.1097/CM9.0000000000000835.
[9]	ZENG DB, DI L, ZHANG RC, et al. The effect of splenectomy on the reversal of cirrhosis: a prospective study[J]. Gastroenterol Res Pract, 2019, 2019: 5459427. DOI: 10.1155/2019/5459427.
[10]	ZHAO YL. Cirrhosis portal hypertension liver fibrosis before and after TIPS Change analysis of indicators[D]. Xining: Qinghai University, 2019. 赵艳玲. 肝硬化门脉高压TIPS术前后肝纤维化指标的变化分析[D]. 西宁: 青海大学, 2019.
[11]	PANG N, ZHAO C, LI J, et al. Body mass index changes after transjugular intrahepatic portosystemic shunt in individuals with cirrhosis[J]. Nutrition, 2021, 84: 111095. DOI: 10.1016/j.nut.2020.111095.
[12]	MATSUDA M, SEKI E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis[J]. Semin Liver Dis, 2020, 40(3): 307-320. DOI: 10.1055/s-0040-1708876.
[13]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
[14]	XUE Y, QIAN K, SUN Y, et al. Application of TGF-β1, TIMP-1 and TIMP-2 small interfering RNAs can alleviate CCl4-induced hepatic fibrosis in rats by rebalancing Th1/Th2 cytokines[J]. Exp Ther Med, 2021, 22(3): 963. DOI: 10.3892/etm.2021.10395.
[15]	LACHOWSKI D, CORTES E, RICE A, et al. Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis[J]. Sci Rep, 2019, 9(1): 7299. DOI: 10.1038/s41598-019-43759-6.
[16]	ZHANG J, LIU Y, CHEN H, et al. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization[J]. Cell Death Dis, 2022, 13(4): 411. DOI: 10.1038/s41419-022-04802-z.
[17]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[18]	CAMPANA L, ESSER H, HUCH M, et al. Liver regeneration and inflammation: from fundamental science to clinical applications[J]. Nat Rev Mol Cell Biol, 2021, 22(9): 608-624. DOI: 10.1038/s41580-021-00373-7.
[19]	SHOKRAVI S, BORISOV V, ZAMAN BA, et al. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review[J]. Stem Cell Res Ther, 2022, 13(1): 192. DOI: 10.1186/s13287-022-02825-z.
[20]	WU W, LI L, YANG J, et al. Therapeutic effect of biejiaxiaozheng pills on carbon tetrachloride-induced hepatic fibrosis in rats through the NF-κB/Nrf2 pathway[J]. Gastroenterol Res Pract, 2021, 2021: 3954244. DOI: 10.1155/2021/3954244.
[21]	KAMM DR, MCCOMMIS KS. Hepatic stellate cells in physiology and pathology[J]. J Physiol, 2022, 600(8): 1825-1837. DOI: 10.1113/JP281061.
[22]	KUMAR V, XIN X, MA J, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113888. DOI: 10.1016/j.addr.2021.113888.
[23]	JIANG H, LIU J, ZHANG K, et al. Saikosaponin D inhibits the proliferation and promotes the apoptosis of rat hepatic stellate cells by inducing autophagosome formation[J]. Evid Based Complement Alternat Med, 2021, 2021: 5451758. DOI: 10.1155/2021/5451758.
[24]	XIU AY, DING Q, LI Z, et al. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K/Akt/mTOR signaling pathway[J]. Drug Des Devel Ther, 2021, 15: 3643-3659. DOI: 10.2147/DDDT.S317701.
[25]	YU HX, YAO Y, BU FT, et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells[J]. Mol Immunol, 2019, 107: 29-40. DOI: 10.1016/j.molimm.2019.01.004.
[26]	GUO Q, CHEN M, CHEN Q, et al. Silencing p53 inhibits interleukin 10-induced activated hepatic stellate cell senescence and fibrotic degradation in vivo[J]. Exp Biol Med (Maywood), 2021, 246(4): 447-458. DOI: 10.1177/1535370220960391.
[27]	CIERPKA R, WEISKIRCHEN R, ASIMAKOPOULOS A. Perilipin 5 ameliorates hepatic stellate cell activation via SMAD2/3 and SNAIL signaling pathways and suppresses STAT3 activation[J]. Cells, 2021, 10(9): 2184. DOI: 10.3390/cells10092184.
[28]	MIRANDA JF, SCARINCI LD, RAMOS LF, et al. The modulatory effect of triclosan on the reversion of the activated phenotype of LX-2 hepatic stellate cells[J]. J Biochem Mol Toxicol, 2020, 34(1): e22413. DOI: 10.1002/jbt.22413.
[29]	LI D, LI W, CHEN Y, et al. Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl₄-induced hepatic fibrosis in rats[J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50(5): 491-498. DOI: 10.1093/abbs/gmy024.
[30]	MANKA P, ZELLER A, SYN WK. Fibrosis in chronic liver disease: An update on diagnostic and treatment modalities[J]. Drugs, 2019, 79(9): 903-927. DOI: 10.1007/s40265-019-01126-9.
[31]	TIAN G, KONG D, JIANG T, et al. Complications after percutaneous ultrasound-guided liver biopsy: A systematic review and meta-analysis of a population of more than 12, 000 patients from 51 cohort studies[J]. J Ultrasound Med, 2020, 39(7): 1355-1365. DOI: 10.1002/jum.15229.
[32]	BOYD A, CAIN O, CHAUHAN A, et al. Medical liver biopsy: background, indications, procedure and histopathology[J]. Frontline Gastroenterol, 2020, 11(1): 40-47. DOI: 10.1136/flgastro-2018-101139.
[33]	LEOW WQ, BEDOSSA P, LIU F, et al. An improved qfibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis (NASH) clinical trials[J]. Diagnostics (Basel), 2020, 10(9): 643. DOI: 10.3390/diagnostics10090643.
[34]	DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38(9): 1562-1570. DOI: 10.1111/liv.13688.
[35]	MÁIZ CARRO L, MARTÍNEZ-GARCÍA MA. Use of Hyaluronic Acid (HA) in chronic airway diseases[J]. Cells, 2020, 9(10): 2210. DOI: 10.3390/cells9102210.
[36]	KIM EM, PARK JW, LEE SM, et al. Diagnostic performance of 2-D shear wave elastography on the evaluation of hepatic fibrosis with emphasis on impact of the different region-of-interest methods[J]. Ultrasound Med Biol, 2022, 48(2): 198-208. DOI: 10.1016/j.ultrasmedbio.2021.09.020.
[37]	CUI XW, LI KN, YI AJ, et al. Ultrasound elastography[J]. Endosc Ultrasound, 2022. DOI: 10.4103/EUS-D-21-00151.[OnlineaheadofPrint]
[38]	LEFEBVRE T, WARTELLE-BLADOU C, WONG P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis[J]. Eur Radiol, 2019, 29(12): 6477-6488. DOI: 10.1007/s00330-019-06331-4.
[39]	WU CY, HSIEH HH, CHU PA, et al. Comparison of ¹⁸F-FDG, ¹⁸F-Fluoroacetate, and ¹⁸F-FEPPA for imaging liver fibrosis in a bile duct-ligated rat model[J]. Mol Imaging, 2021, 2021: 7545284. DOI: 10.1155/2021/7545284.